Welcome to our dedicated page for Lifecore Biomedical news (Ticker: LFCR), a resource for investors and traders seeking the latest updates and insights on Lifecore Biomedical stock.
Lifecore Biomedical, Inc. (LFCR) reports developments as a fully integrated injectables CDMO focused on sterile pharmaceutical products. The company provides development, fill and finish services for syringes, vials and cartridges, including complex formulations, and manufactures injectable-grade hyaluronic acid for biopharmaceutical and biotechnology customers.
Company news commonly covers financial results, revenue and Adjusted EBITDA guidance, commercial site transfer programs, technical transfer and PPQ work, new CDMO manufacturing service agreements, customer program expansions, cost-containment initiatives, biomanufacturing conference participation and Nasdaq inducement equity grants.
Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The conference is scheduled to take place from January 13-16, 2025, in San Francisco, California.
The company's management team, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will be conducting one-on-one meetings during the conference. This participation represents an important opportunity for Lifecore to engage with healthcare industry stakeholders and investors.
Lifecore Biomedical (NASDAQ: LFCR) reported Q2 fiscal 2025 results with revenues of $32.6 million, up 8% year-over-year. The company recorded a net loss of $6.6 million ($0.25 per share) compared to net income of $14.2 million in the prior year period. Adjusted EBITDA increased to $6.5 million from $5.4 million.
Key developments include signing two new project agreements, completing installation of a high-speed multi-purpose 5-head isolator filler that doubles capacity, and strengthening the balance sheet through a $24.3 million private placement and favorable restructuring of the BMO credit facility. Gross profit improved to $11.1 million, while operating expenses increased primarily due to higher stock-based compensation and professional fees.
The company regained Nasdaq compliance and made several key leadership appointments, including a new CFO and executives in operations, HR, and quality services.
Lifecore Biomedical (NASDAQ: LFCR), a contract development and manufacturing organization (CDMO), has scheduled its second quarter fiscal 2025 financial results announcement for January 2, 2025, after market close. The company's senior management will host a webcast at 4:30 p.m. Eastern Time to discuss the quarterly results and recent corporate developments. The webcast will be accessible through Lifecore's investor relations website, with a replay available for at least 14 days following the live presentation.
Lifecore Biomedical (NASDAQ: LFCR) has been selected by Nirsum Laboratories to provide CDMO services for their lead candidate NRS-033, a novel treatment for opioid and alcohol use disorders entering Phase 2 clinical development.
The agreement encompasses assessment and technology transfer of fill and finish processes for NRS-033, leveraging Lifecore's expertise in sterile injectable pharmaceuticals. Lifecore will provide filled syringes for clinical development, with potential to create a comprehensive development and commercialization plan for the entire fill and finish process.
Lifecore Biomedical has announced an amendment and extension of its asset-based lending revolving credit facility with BMO. The amendment extends the facility term by three years to November 2027, simplifies and reduces interest rates, and provides greater flexibility regarding covenants and reporting requirements. This follows the company's recent $24.3 million private placement financing.
The company has also implemented operational initiatives including key management appointments, expansion of manufacturing capabilities through a new high-speed multi-purpose isolator filler, and securing new customer agreements, notably with Lindy Biosciences.
Lifecore Biomedical (NASDAQ: LFCR), a fully integrated contract development and manufacturing organization (CDMO), hosted a virtual investor day on November 21, 2024. During this event, Lifecore's senior management team discussed the company's business and future growth strategies. A replay of the event is available via webcast and can be accessed through the Events & Presentations section of Lifecore's investor web page.
Lifecore Biomedical (NASDAQ: LFCR) has announced its participation in the upcoming Stephens Annual Investment Conference, scheduled for November 19-21, 2024, in Nashville, Tennessee. The company's president and CEO, Paul Josephs, will be featured in a fireside chat on Tuesday, November 19, 2024, at 2:00 p.m. Central time at the Grand Hyatt Nashville. Additionally, Lifecore management will be available for one-on-one meetings during the conference.
Lifecore Biomedical (NASDAQ: LFCR) has announced plans to host a virtual investor day on Thursday, November 21, 2024, from 8:00 to 9:30 a.m. Eastern Time. The event, scheduled before market opening, will feature presentations from the company's senior management team discussing business strategies and future growth plans.
Interested participants can access the live webcast or archived recording through the Events & Presentations section on Lifecore's investor webpage at ir.lifecore.com/events-presentations. The company, operating as a fully integrated contract development and manufacturing organization (CDMO), aims to provide comprehensive insights into its operations and future direction.
Lifecore Biomedical (NASDAQ: LFCR) has announced key leadership changes with the appointment of Thomas Guldager as Vice President of Operations and Jackie Klecker as Executive Vice President of Quality and Development Services. This organizational restructuring separates operations and quality functions to support the company's growth strategy. Guldager brings 20 years of pharmaceutical industry experience, most recently from Xellia Pharmaceuticals. The company has recently doubled its capacity through a new 5-head isolator filler installation. Klecker, with over 30 years of industry experience and 16 years at Lifecore, will focus on maintaining the company's 40+ year regulatory track record and quality management system.
Lifecore Biomedical (NASDAQ: LFCR) reported Q1 fiscal 2025 financial results and provided a corporate update. Key highlights include:
1. Revenues of $24.7 million for Q1 fiscal 2025
2. Installation of a 5-head isolator filler, more than doubling capacity and increasing revenue generating potential to up to $300 million annually
3. Successful closing of financing, raising approximately $24.3 million
4. Signing of multiple new business agreements with new and existing customers
5. Reaffirmation of fiscal year 2025 guidance for both revenue and Adjusted EBITDA
6. Net loss of $16.2 million or $0.53 per diluted share for Q1
7. Adjusted EBITDA of $(1.8) million for Q1
The company aims to focus on maximizing existing business, advancing its development pipeline, and pursuing new business opportunities.